Advanced RNAi Launches Will Harness Demographic And Health Trends
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 14 Analysts
Published
05 Aug 25
Updated
16 Aug 25
AnalystHighTarget's Fair Value
US$80.00
75.2% undervalued intrinsic discount16 Aug
US$19.86
1Y
-15.8%7D
11.6%